Clinical Trials at University of Iowa Hospitals and Clinics
As of August 2026, 56 paid clinical trials are recruiting at University of Iowa Hospitals and Clinics, located at 200 HAWKINS DR, DEPARTMENT OF SURGERY, 1529 JCP, IOWA CITY, IA 52242-1009, phone (319) 467-5302 in Iowa City, Iowa. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Breast Cancer and Multiple Myeloma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
56 clinical trials at University of Iowa Hospitals and Clinics
·Clear filters·A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Onyx™ Liquid Embolic IDE Clinical Study
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
The Artisse™ Intrasaccular Device is Indicated for the Treatment of Wide-neck Bifurcating Intracranial Aneurysms (IAs).
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC
A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
Test-retest Evaluation of [18F]F-AraG PET
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
Adjuvant Steroid Outcomes in Idiopathic Subglottic Stenosis
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
TSC Biosample Repository and Natural History Database
Paced Heart Rate Acceleration for Cardiac Conditioning
Carbon Dioxide (CO2) Chemosensitivity and SUDEP
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Hyperbaric Oxygen Brain Injury Treatment Trial
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
Common conditions studied in Iowa City
- Acute Myeloid Leukemia (11 active studies)
- Breast Cancer (11 active studies)
- Multiple Myeloma (8 active studies)
- Hearing Loss, Sensorineural (5 active studies)
- Non-Hodgkin Lymphoma (5 active studies)
- Bladder Cancer (4 active studies)
Leading research sponsors in Iowa City
- University of Iowa
- National Cancer Institute (NCI)
- Children's Oncology Group
- Novartis Pharmaceuticals
- Anna Stanhewicz, PhD
Frequently asked questions
How many paid clinical trials are currently recruiting in Iowa City?
There are approximately 551 recruiting clinical trials in Iowa City, Iowa listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Iowa City pay participants?
Most recruiting trials in Iowa City compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Iowa City?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Iowa City?
The most common conditions under active study in Iowa City include Acute Myeloid Leukemia (11), Breast Cancer (11), Multiple Myeloma (8), Hearing Loss, Sensorineural (5), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Iowa City?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Iowa City on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Iowa City?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Iowa City?
Recruiting research sites in Iowa City include University of Iowa, University of Iowa/Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Iowa City right now?
The largest active categories in Iowa City are Cancer & tumors (178), Neurology & pain (32), Cardiovascular (26). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of University of Iowa Hospitals and Clinics?
University of Iowa Hospitals and Clinics is located at 200 HAWKINS DR, DEPARTMENT OF SURGERY, 1529 JCP, IOWA CITY, IA 52242-1009. Use the Google Maps link in the intro above to get directions.
How do I contact University of Iowa Hospitals and Clinics?
You can reach University of Iowa Hospitals and Clinics by phone at (319) 467-5302. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.